Key result
The SYT-SSX1 fusion transcript showed a non-significant trend toward reduced metastasis-free survival compared to SYT-SSX2 in patients with synovial sarcoma (adjusted HR 1.61).
Why the study?
Does the SYT-SSX1 fusion transcript predict reduced metastasis-free survival and correlate with histologic subtype in synovial sarcoma?
Cohort (n=64)
No
Does the SYT-SSX1 fusion transcript predict reduced metastasis-free survival and correlate with histologic subtype in synovial sarcoma?
Effect estimate: HR 1.61 (95% CI 0.80-3.23)
p-value: p=0.183
The SYT-SSX1 fusion transcript may be associated with reduced metastasis-free survival and the biphasic histologic subtype in synovial sarcoma.
No takes yet. Share an insight, caveat, or question.
May support further SYT-SSX1 investigation in synovial sarcoma; hypothesis-generating and should not yet change practice.
Mezzelani et al. (2001) conducted a cohort in Synovial Sarcoma (n=64). SYT-SSX1 fusion transcript vs. SYT-SSX2 fusion transcript was evaluated on Metastasis-free survival (HR 1.61, 95% CI 0.80-3.23, p=0.183). The SYT-SSX1 fusion transcript showed a non-significant trend toward reduced metastasis-free survival compared to SYT-SSX2 in patients with synovial sarcoma (adjusted HR 1.61).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: